التفاصيل البيبلوغرافية
| العنوان: |
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients. |
| المؤلفون: |
Antoniou, Tony, Szadkowski, Leah, Walmsley, Sharon, Cooper, Curtis, Burchel, Ann N., Bayoumi, Ahmed M., Montaner, Julio S. G., Loutfy, Mona, Klein, Marina B., Machouf, Nima, Tsoukas, Christos, Wong, Alexander, Hogg, Robert S., Raboud, Janet, Burchell, Ann N, Canadian Observational Cohort (CANOC) collaboration |
| المصدر: |
BMC Infectious Diseases; 4/11/2017, Vol. 17, p1-10, 10p, 4 Charts, 1 Graph |
| مصطلحات موضوعية: |
ATAZANAVIR, HIV-positive persons, RITONAVIR, HIV protease inhibitors, VIROLOGY, COMBINATION drug therapy, COMPARATIVE studies, HIV, LONGITUDINAL method, RESEARCH methodology, MEDICAL cooperation, RESEARCH, RESEARCH funding, EVALUATION research, RETROSPECTIVE studies, ANTI-HIV agents, THERAPEUTICS |
| مصطلحات جغرافية: |
BRITISH Columbia, CANADA |
| مستخلص: |
Background: Atazanavir/ritonavir and darunavir/ritonavir are common protease inhibitor-based regimens for treating patients with HIV. Studies comparing these drugs in clinical practice are lacking.Methods: We conducted a retrospective cohort study of antiretroviral naïve participants in the Canadian Observational Cohort (CANOC) collaboration initiating atazanavir/ritonavir- or darunavir/ritonavir-based treatment. We used separate Fine and Gray competing risk regression models to compare times to regimen failure (composite of virologic failure or discontinuation for any reason). Additional endpoints included virologic failure, discontinuation due to virologic failure, discontinuation for other reasons, and virologic suppression.Results: We studied 222 patients treated with darunavir/ritonavir and 1791 patients treated with atazanavir/ritonavir. Following multivariable adjustment, there was no difference between darunavir/ritonavir and atazanavir-ritonavir in the risk of regimen failure (adjusted hazard ratio 0.76, 95% CI 0.56 to 1.03) Darunavir/ritonavir-treated patients were at lower risk of virologic failure relative to atazanavir/ritonavir treated patients (aHR 0.50, 95% CI 0.28 to 0.91), findings driven largely by high rates of virologic failure among atazanavir/ritonavir-treated patients in the province of British Columbia. Of 108 discontinuations due to virologic failure, all occurred in patients starting atazanavir/ritonavir. There was no difference between regimens in time to discontinuation for reasons other than virologic failure (aHR 0.93; 95% CI 0.65 to 1.33) or virologic suppression (aHR 0.99, 95% CI 0.82 to 1.21).Conclusions: The risk of regimen failure was similar between patients treated with darunavir/ritonavir and atazanavir/ritonavir. Although darunavir/ritonavir was associated with a lower risk of virologic failure relative to atazanavir/ritonavir, this difference varied substantially by Canadian province and likely reflects regional variation in prescribing practices and patient characteristics. [ABSTRACT FROM AUTHOR] |
|
Copyright of BMC Infectious Diseases is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder